RT／PCR检测CMLbcr／abl　mRNA及α－干扰素治疗后残留病灶观察  

DETECTION OF BCR/ABL mRNA BY POLYMERASECHAIN REACTION AND MONITORING OF THE MINIMALRESIDUAL DISEASE AFTER THE ALPHA-INTERFERONTHERAPY IN CHRONIC MYELOGENOUS LEUKEMIA

作　　者：黄一微 卢珊[1] 谢毅[1] 姬美容[1] 丁训杰[1] 

机构地区：[1]上海医科大学华山医院

出　　处：《中华血液学杂志》1995年第1期20-22,共3页Chinese Journal of Hematology

基　　金：国家自然科学基金

摘　　要：应用逆转录／多聚酶链反应（ＲＴ／ＰＣＲ）及双扩增ＰＣＲ方法检测了４４例慢性期、缓解期及加速（或）急变期慢性粒细胞白血病患者的ｂｃｒ／ａｂｌｍＲＮＡ，所有患者均为阳性。各期患者均以表达ｂ＿３ａ＿２融合方式为主。１４例患者单用α－２ｂ干扰素或合用小剂量羟基脲治疗后，１３例患者ｂｃｒ／ａｂｌｍＲＮＡ仍阳性，有３例单次扩增结果阴性，提示白血病细胞负荷较低，１例孤立性骨髓外粒细胞白血肉瘤患者经治疗后复查ｂｃｒ／ａｂｌｍＲＮＡ转阴。但按作者应用的剂量及疗程对大多数患者尚难彻底清除残留病灶。he bcr/abl fusion gene transcripts of 44 patients withchronic myelogenous leukemia were assayed by RT/PCRand nested PCR. The majority patients showed b_3a_2mRNA. The bcr/abl mRNA still can be detected in 13 out of14 patients treated with interferon alpha-2b or plus lowdose hydroxyurea, but the first round of amplificationshowed negative in 3 of these 13 patients,indicating thatthe leukemic cell loads were low in these patients. Onepatient with solitary extramedullary myelosarcoma with-out bone marrow involvement become bcr/abl mRNAnegative after the treatment. The results indicate that itis difficult to eradicate the minimal residual disease in themajority of patients with the conventional doses andcourses of alpha-interferon used at present in our coun-try.

关 键 词：白血病 髓细胞性 慢性 逆转录 聚合酶链反应 

分 类 号：R733.72[医药卫生—肿瘤]